Needham & Company LLC Downgrades Day One Biopharmaceuticals (NASDAQ:DAWN) to Hold

Day One Biopharmaceuticals (NASDAQ:DAWN) was downgraded by research analysts at Needham & Company LLC from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, MarketBeat.com reports.

Several other brokerages have also recently issued reports on DAWN. HC Wainwright decreased their price objective on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. JPMorgan Chase & Co. raised their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Zacks Research downgraded shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Wedbush boosted their price target on shares of Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Hold” and an average target price of $25.56.

Day One Biopharmaceuticals Trading Up 65.9%

Shares of NASDAQ DAWN opened at $21.20 on Friday. The stock has a market cap of $2.19 billion, a P/E ratio of -20.58 and a beta of -1.25. The business’s fifty day simple moving average is $11.10 and its 200-day simple moving average is $9.06. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $21.23.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The company had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. On average, equities analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 6,065 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $70,354.00. Following the completion of the sale, the chief financial officer owned 312,025 shares in the company, valued at $3,619,490. This represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Adam Dubow sold 6,395 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $74,182.00. Following the sale, the insider owned 72,694 shares of the company’s stock, valued at approximately $843,250.40. This represents a 8.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,461 shares of company stock worth $422,948 over the last 90 days. Company insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. purchased a new position in shares of Day One Biopharmaceuticals during the third quarter worth about $39,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after acquiring an additional 1,029 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in Day One Biopharmaceuticals by 44.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after acquiring an additional 2,264 shares during the last quarter. Quarry LP acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth approximately $49,000. Finally, Entropy Technologies LP acquired a new stake in Day One Biopharmaceuticals during the 2nd quarter worth approximately $67,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Key Headlines Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.